{"id":"W2117923445","doi":"10.1093/rheumatology/ken326","title":"Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance: reply","year":2008,"lang":"en","type":"article","venue":"Lara D. Veeken","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre for Advancing Health Outcomes; University of British Columbia","funders":"","keywords":"Medicine; Adalimumab; Ankylosing spondylitis; Infliximab; Etanercept; Nice; Spondylitis; Dermatology; Tumor necrosis factor alpha; Physical therapy; Internal medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01316966,0.002068108,0.003528793,0.002343488,0.003577257,0.005758158,0.005821196,0.0647029,0.01058824],"category_scores_gemma":[0.1034459,0.001560731,0.004739868,0.001808846,0.005161503,0.007797023,0.002507764,0.0501524,0.01283608],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.005403931,"about_ca_system_score_gemma":0.006920194,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005506568,"about_ca_topic_score_gemma":0.005215408,"domain_scores_codex":[0.986343,0.003005537,0.002672814,0.001747014,0.005182683,0.001048931],"domain_scores_gemma":[0.9410083,0.02995556,0.003922907,0.001697287,0.01899737,0.004418518],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00003750095,0.000007222801,0.00006651251,0.0001057036,0.00001457066,0.0001232274,0.00003265246,0.00001699539,0.00003583864,0.0003013528,0.9982513,0.001007185],"study_design_scores_gemma":[0.0002922777,0.0001170411,0.001056987,0.001244738,0.0001434639,0.001474748,0.0003418118,0.0003185494,0.0003880062,0.004989505,0.9894805,0.0001522676],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.0001191392,0.001346448,0.0001507035,0.7939882,0.2034244,0.00002963173,0.0002212734,0.00009360722,0.0006266618],"genre_scores_gemma":[0.0007251832,0.0008066724,0.000225144,0.8640187,0.1322145,0.00004734733,0.00005667766,0.00006550128,0.00184023],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.0647029,"threshold_uncertainty_score":0.06964868,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07076017386767676,"score_gpt":0.3383893499982589,"score_spread":0.2676291761305822,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}